Xultophy ([insulin degludec + liraglutide]; Novo Nordisk) is a once-daily, injectable combination product comprising a fixed ratio of Novo Nordisk’s long-lasting basal insulin Tresiba (insulin degludec) and glucagon-like peptide-1 receptor agonist Victoza (liraglutide) for the treatment of type 2 diabetes. Dosing is titrated according to insulin, and can therefore be adjusted from patient to patient. A key benefit of the combined dosing is the increase in efficacy over component products with a comparatively lower dose of each. Xultophy is administered via a prefilled device which utilizes the same platform as Novo Nordisk’s FlexTouch device.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Xultophy : Diabetes type 2
LIST OF FIGURES 9 Figure 1: Xultophy for type 2 diabetes – SWOT analysis
10 Figure 1: Datamonitor Healthcare’s drug assessment of Xultophy
11 Figure 2: Datamonitor Healthcare’s drug assessment scorecard for Xultophy compared to Lantus
LIST OF TABLES 6 Table 1: Xultophy pivotal trial data in type 2 diabetes
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726